# NexPoint Life Sciences III DST

> The Offering is designed for Accredited Investors seeking to participate in a Section 1031 Exchange as well as those seeking a quality real estate investment.

Source: https://baker1031.com/invest/nexpoint-life-sciences-iii-dst


## Key terms

| Term | Value |
|---|---|
| Status | Limited availability |
| Property type | Industrial |
| Sponsor | NexPoint |
| Location | Minnesota |
| Minimum investment | $100,000 |
| Year-1 projected distribution | 4.18% |
| Average projected distribution | 4.07% |
| Projected hold | 5–9 yrs |
| Offering size | $61,961,253 |
| Equity raise | $30,661,253 |
| Debt | $31,300,000 |
| Loan-to-value | 50.5% |
| 721 exit | Optional |

## Projected distributions by year

| Year | Projected distribution |
|---|---|
| Year 1 | 4.18% |
| Year 2 | 4.03% |
| Year 3 | 4.01% |
| Year 4 | 4.04% |
| Year 5 | 4.06% |
| Year 6 | 4.06% |
| Year 7 | 4.07% |
| Year 8 | 4.07% |
| Year 9 | 4.10% |

## Overview

The Offering is designed for Accredited Investors seeking to participate in a Section 1031 Exchange as well as those seeking a quality real estate investment. The Sponsor is pleased to present the opportunity to invest in the Property. The Sponsor believes that the Property presents an attractive long-term investment opportunity due to strong industry tailwinds, high quality construction and infrastructure, a strong Tenant, use fundamental to the Tenant’s business as its corporate headquarters, desirable lease terms (including the 15-year initial duration of the Tenant Lease with extension options), and a strategic location.

The Property, also known as “11200 Hudson Road,” is a medical device research and development facility located at 11200 Hudson Road, Woodbury, Minnesota 55129. As of December 31, 2023, the Property was 100% leased to the Tenant.

The Tenant, Kindeva, is a global contract development and manufacturing organization (“CDMO”) in the pharmaceutical industry, focused on drug-device combination products. The Tenant is an industry leader in combination drug delivery and manufacturing and provides expertise at every stage of pulmonary and nasal, injectable, and transdermal therapy development and manufacturing. The Tenant’s offerings span early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. The Tenant serves a global client base from its nine manufacturing, research, and development facilities located in the United States and United Kingdom.

## Offering documents

Available to registered investors:

- NexPoint - NexPoint Life Sciences III DST - PPM Supplement 1 (PDF)
- NexPoint - NexPoint Life Sciences III DST - PPM Supplement 2 (PDF)
- NexPoint - NexPoint Life Sciences III DST - PPM (PDF)
- PPM Supplement 2 (PDF)
- PPM Supplement 1 (PDF)
- PPM (PDF)

Information reflects my offering records as of October 28, 2026 and may have changed. Projected distributions are the sponsor's estimates, are not guaranteed, may change or stop, and may include a return of capital. To request the offering documents, contact hello@baker1031.com or visit https://baker1031.com/invest/nexpoint-life-sciences-iii-dst.

---

Securities are offered through Aurora Securities, Inc., member FINRA/SIPC. Baker 1031 Investments, LLC is independent of Aurora Securities, Inc. and is not a registered broker-dealer or investment adviser. This content is general education, not investment, tax, or legal advice, and is not an offer to buy or sell securities. Offers are made only through the offering documents to eligible investors, generally accredited investors. DST interests are illiquid, distributions are not guaranteed, and you can lose your entire investment.

Contact: Jerry Baker, Baker 1031 Investments · hello@baker1031.com · (415) 965-0552 · https://baker1031.com/contact